Press release
Fabry Disease Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Pipeline, Medication, Prevalence and Companies by DelveInsight
Fabry Disease Treatment Market
(Albany, USA) DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Fabry Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Fabry Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Fabry Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Fabry Disease market.
Request for a Free Sample Report @ [https://www.delveinsight.com/report-store/neuropathic-pain-market?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=apr]
Some facts of the Fabry Disease Market Report are:
* According to DelveInsight, Fabry Disease market size is expected to grow at a decent CAGR by 2032.
* As per DelveInsight analysis, the Fabry disease market size in the 7MM was approximately USD ~1.3 billion in 2022.
* As per the analysis conducted by DelveInsight, in 2022 the total diagnosed prevalent cases of Fabry disease was 15,290 in the 7MM and these cases are further projected to increase during the study period (2019-2032).
* Leading Fabry Disease companies working in the market are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others.
* Key Fabry Disease Therapies expected to launch in the market are PRX-102 (Pegunigalsidase Alfa), Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, and others.
* On March 2024, Sanofi announced results of a Phase 4 study which evaluates the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
* On April 2024, 4D Molecular Therapeutics announced results of an Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement
Fabry Disease Overview
Fabry disease is an inherited lysosomal storage disorder caused by a nonfunctional or partially functional enzyme called alpha-galactosidase A (-Gal A). Reduced -Gal A activity in lysosomes leads to the accumulation of enzyme substrates (Gb3 and lyso-Gb3), which causes cellular damage in tissues throughout the body.
Despite being X-linked, heterozygous women may experience all of the signs and symptoms seen in men; however, when compared to hemizygous males, the signs and symptoms of Fabry disease in women typically appear later and with less severity.
Fabry disease symptoms include pain that spreads throughout the body (called a Fabry crisis), gastrointestinal complications, headaches, impaired sweating, vertigo, and hearing loss. Several tests, such as enzyme assay and newborn screening, are used for Fabry disease diagnosis.
Learn more about Fabry Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Fabry Disease Drugs Market [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Fabry Disease Market
The Fabry Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Fabry Disease market trends by analyzing the impact of current Fabry Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Fabry Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Fabry Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Fabry Disease market in 7MM is expected to witness a major change in the study period 2019-2032.
Fabry Disease Epidemiology
The Fabry Disease epidemiology section provides insights into the historical and current Fabry Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Fabry Disease market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Fabry Disease Epidemiology @ [https://www.delveinsight.com/report-store/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
As per DelveInsight's assessments, in the 7MM Fabry Disease is more prevalent in males than in females but there are some differences at the regional level
Fabry Disease Drugs Uptake
This section focuses on the uptake rate of the potential Fabry Disease drugs recently launched in the Fabry Disease market or expected to be launched in 2019-2032. The analysis covers the Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Fabry Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Fabry Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Fabry Disease Pipeline Development Activities
The Fabry Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Fabry Disease key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Fabry Disease pipeline development activities @ Fabry Disease Clinical Trials and Advancements [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Fabry Disease Pipeline Therapies and Key Companies
* PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics
* Venglustat: Sanofi Genzyme
* ST-920: Sangamo Therapeutics
* FLT190: Freeline Therapeutics
* 4D-310: 4D Molecular Therapeutics
* Lucerastat: Idorsia Pharmaceuticals
* Moss-aGal: GREENOVATION BIOTECH GMBH
Fabry Disease Therapeutics Assessment
Major key companies are working proactively in the Fabry Disease Therapeutics market to develop novel therapies which will drive the Fabry Disease treatment markets in the upcoming years are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, others
Learn more about the emerging Fabry Disease therapies & key companies @ Fabry Disease Treatment Market [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Fabry Disease Report Key Insights
1. Fabry Disease Patient Population
2. Fabry Disease Market Size and Trends
3. Key Cross Competition in the Fabry Disease Market
4. Fabry Disease Market Dynamics (Key Drivers and Barriers)
5. Fabry Disease Market Opportunities
6. Fabry Disease Therapeutic Approaches
7. Fabry Disease Pipeline Analysis
8. Fabry Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Fabry Disease Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Fabry Disease Competitive Intelligence Analysis
4. Fabry Disease Market Overview at a Glance
5. Fabry Disease Disease Background and Overview
6. Fabry Disease Patient Journey
7. Fabry Disease Epidemiology and Patient Population
8. Fabry Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Fabry Disease Unmet Needs
10. Key Endpoints of Fabry Disease Treatment
11. Fabry Disease Marketed Products
12. Fabry Disease Emerging Therapies
13. Fabry Disease Seven Major Market Analysis
14. Attribute Analysis
15. Fabry Disease Market Outlook (7 major markets)
16. Fabry Disease Access and Reimbursement Overview
17. KOL Views on the Fabry Disease Market
18. Fabry Disease Market Drivers
19. Fabry Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fabry-disease-treatment-market-2032-ema-pdma-fda-approvals-clinical-trials-pipeline-medication-prevalence-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Pipeline, Medication, Prevalence and Companies by DelveInsight here
News-ID: 3816063 • Views: …
More Releases from ABNewswire
RC Adventures, LLC Opens Community-Focused Hobby Shop with Indoor Rock Crawling …
RC Adventures, LLC has opened its doors as a comprehensive remote control hobby destination featuring both brick-and-mortar and online shopping experiences. The new store distinguishes itself with an indoor rock crawling course, dedicated kids' sandbox, construction equipment dirt area, and rental services, creating a community hub for RC enthusiasts of all ages and skill levels.
RC Adventures, LLC has officially launched operations as a full-service remote control hobby destination, combining traditional…
Caneca Coffee Roasters Launches with Experiential Approach to Specialty Coffee, …
Caneca Coffee Roasters has entered the specialty coffee market with a distinctive philosophy that positions every bean as a story and every cup as a transformative journey. The new roastery offers carefully crafted blends including Shanta's Fruit, Golden Dawn Blend, Espresso Blend, House Blend, and a bold DECAF option, each designed to capture vibrant flavors from the world's finest coffee-growing regions.
Caneca Coffee Roasters has officially launched operations with an experiential…
Atlanta's Trio Tailoring, LLC Celebrates Over a Decade of Making Custom Clothing …
Trio Tailoring, LLC marks more than ten years of serving Atlanta's professional community with affordable, high-quality custom clothing. The established clothier has become the go-to destination for wedding grooms, attorneys, and corporate professionals seeking personalized garments that deliver exceptional value without compromising on craftsmanship or style.
Since establishing its presence in Atlanta's fashion and professional apparel market over a decade ago, Trio Tailoring, LLC has built a loyal following among discerning…
Dr. Chris Chlebowski Introduces Axobotanica, a New Product and Education Brand B …
Internationally recognized educator and speaker Dr. Chris Chlebowski is bringing his two decades of professional experience to consumers through Axobotanica-a family-owned retail and education brand offering thoughtfully crafted products and clear, trustworthy information. The company reflects a commitment to quality, transparency, and meaningful customer experiences.
Axobotanica LLC launches as a new product and education brand shaped by nearly twenty years of professional experience. Co-founded by Dr. Chris Chlebowski, the platform blends…
More Releases for Fabry
Key Factor Supporting Global Fabry Disease Treatment Market Development in 2025: …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Fabry Disease Treatment Market Size By 2025?
The valuation of the Fabry disease treatment market has experienced robust expansion recently, projected to advance from $2.09 billion in 2024 up to $2.27 billion by 2025, reflecting an 8.8% compound annual growth rate during this timeframe. This…
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
